PMID- 35673884
OWN - NLM
STAT- MEDLINE
DCOM- 20220609
LR  - 20220716
IS  - 1526-2359 (Electronic)
IS  - 1073-2748 (Print)
IS  - 1073-2748 (Linking)
VI  - 29
DP  - 2022 Jan-Dec
TI  - PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced 
      Non-Small Cell Lung Cancer.
PG  - 10732748221107590
LID - 10.1177/10732748221107590 [doi]
LID - 10732748221107590
AB  - BACKGROUND: With the use of immune-checkpoint inhibitors (ICIs) in advanced or 
      metastatic non-small cell lung cancer (NSCLC), whether ICIs or chemotherapy is 
      more effective still remains controversial. This study was conducted to evaluate 
      the efficacy of programmed cell death 1 (PD-1), programmed cell death ligand 1 
      (PD-L1), cytotoxic T-lymphocyte protein 4 (CTLA-4) alone or in their combination 
      vs chemotherapy in patients with advanced or metastatic NSCLC. METHODS: This 
      meta-analysis was conducted from PubMed, Web of Science, Medline, Embase, and the 
      Cochrane Library up to March 2021 to identify relevant randomized controlled 
      trials. Primary endpoints were overall survival (OS) and progression-free 
      survival (PFS). Secondary endpoint was adverse events (AEs). This meta-analysis's 
      Prospero registration number is CRD42022323570. RESULTS: The search process has 
      identified 13 studies containing 7918 patients with advanced or metastatic NSCLC. 
      The benefit of PD-1/L1 or CTLA-4 inhibitors alone or in combination compared with 
      chemotherapy for advanced or metastatic NSCLC was elucidated in both OS [HR = 
      .75, 95% CI (.70-.80), P < .001] and PFS [HR = .83, 95% CI (.73-.95), P < .001]. 
      Besides, ICIs were associated with fewer AEs compared to chemotherapy. 
      CONCLUSION: PD-1/L1 or CTLA-4 inhibitors alone or in combination, with fewer AEs, 
      was associated with significant improvements in terms of OS and PFS than 
      chemotherapy in advanced or metastatic NSCLC.
FAU - Guo, Luyong
AU  - Guo L
AD  - The Emergency Department, 74784Zhuji People's Hospital, Shaoxing, China.
FAU - Liang, Jiali
AU  - Liang J
AD  - The First Clinical Medical College, 70571Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Dai, Wei
AU  - Dai W
AD  - The Second Clinical Medical College, RinggoldID:70571Zhejiang Chinese Medical 
      University, Hangzhou, China.
FAU - Li, Jiayu
AU  - Li J
AD  - The Second Clinical Medical College, RinggoldID:70571Zhejiang Chinese Medical 
      University, Hangzhou, China.
FAU - Si, Yuexiu
AU  - Si Y
AD  - School of Basic Medical Sciences, 70571Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Ren, Wei
AU  - Ren W
AD  - The First Clinical Medical College, 70571Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Lu, Yan
AU  - Lu Y
AD  - The First Clinical Medical College, 70571Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Chen, Danqi
AU  - Chen D
AUID- ORCID: 0000-0003-2449-3885
AD  - Intensive Care Unit, 301513Ningbo Yinzhou No. 2 Hospital, Ningbo, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Cancer Control
JT  - Cancer control : journal of the Moffitt Cancer Center
JID - 9438457
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - B7-H1 Antigen
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Lung Neoplasms/pathology
MH  - Programmed Cell Death 1 Receptor/therapeutic use
MH  - Progression-Free Survival
PMC - PMC9185001
OTO - NOTNLM
OT  - CTLA-4
OT  - PD-1/L1
OT  - chemotherapy
OT  - meta-analysis
OT  - non-small cell lung cancer
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/06/09 06:00
MHDA- 2022/06/10 06:00
PMCR- 2022/06/08
CRDT- 2022/06/08 03:23
PHST- 2022/06/08 03:23 [entrez]
PHST- 2022/06/09 06:00 [pubmed]
PHST- 2022/06/10 06:00 [medline]
PHST- 2022/06/08 00:00 [pmc-release]
AID - 10.1177_10732748221107590 [pii]
AID - 10.1177/10732748221107590 [doi]
PST - ppublish
SO  - Cancer Control. 2022 Jan-Dec;29:10732748221107590. doi: 
      10.1177/10732748221107590.